Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun:3:117-125.
doi: 10.1016/j.ijregi.2022.02.007. Epub 2022 Mar 5.

Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020

Cheikh Talla  1 , Cheikh Loucoubar  1 , Jerlie Loko Roka  2 , Mamadou A Barry  1 , Seynabou Ndiaye  1 , Maryam Diarra  1 , Mareme Seye Thiam  1 , Oumar Faye  3 , Moussa Dia  3 , Mamadou Diop  1 , Oumar Ndiaye  3 , Adama Tall  1 , Rokhaya Faye  4 , Adji Astou Mbow  4 , Babacar Diouf  4 , Jean Pierre Diallo  5 , Ibrahima Mamby Keita  5 , Mamadou Ndiaye  5 , Tom Woudenberg  6 , Michael White  6 , Jim Ting  2 , Cheikh Tidiane Diagne  3 , Omer Pasi  2 , Boly Diop  5 , Amadou A Sall  3 , Inès Vigan-Womas  4 , Ousmane Faye  3
Affiliations

Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020

Cheikh Talla et al. IJID Reg. 2022 Jun.

Abstract

Objectives: A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal.

Methods: Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated.

Results: Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20-84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1-30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164-5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity.

Conclusions: These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions.

Keywords: ELISA; IgG and IgM; Population-based survey; SARS-CoV-2; Senegal; Serology; Seroprevalence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of participant enrolment in the anti-SARS-CoV-2 antibody national seroprevalence study in Senegal.
Figure 2
Figure 2
Mapping of clusters investigated and the Senegal COVID-19 epidemic curve from March 2 to December 31, 2020 (Data sourced from the Ministry of Health).
Figure 3
Figure 3
Mapping of the seroprevalence data obtained by ELISA (panels A, B, and C) and COVID-19 attack rate cases at the time of the household sero-survey (panel D).
Figure 4
Figure 4
Association between SARS-CoV-2 prevalence and sociodemographic factors.
See this image and copyright information in PMC

References

    1. Al-Qahtani M, AlAli S, AbdulRahman A, Salman Alsayyad A, Otoom S, Atkin SL. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. International Journal of Infectious Diseases. 2021;102:285–288. doi: 10.1016/j.ijid.2020.10.091. - DOI - PMC - PubMed
    1. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLOS Medicine. 2020;17 doi: 10.1371/journal.pmed.1003346. - DOI - PMC - PubMed
    1. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D, et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. MedRxiv. 2020 doi: 10.1101/2020.07.30.20164970. 2020.07.30.20164970. - DOI
    1. Dia N, Lakh NA, Diagne MM, Mbaye KD, Taieb F, Fall NM, et al. COVID-19 Outbreak, Senegal, 2020. Emerg Infect Dis. 2020;26:2771–2773. doi: 10.3201/eid2611.202615. - DOI - PMC - PubMed
    1. Diop F, Diop G, Niang M, Diouf B, Ndiaye D, Richard V, et al. The value of local malaria strains for serological studies: local strains versus Palo Alto reference strain. Malaria Journal. 2015;14:229. doi: 10.1186/s12936-015-0734-z. - DOI - PMC - PubMed